Department of Molecular Oncology

 
 

Department head: Ragnhild A. Lothe, Professor
Department administrative consultants: Mona Hagen and Linda Uv Mjøen
Lab manager: Guro E. Lind


Research groups:

Genetics Genome Biology Epigenetics
Ragnhild A. Lothe
Rolf I. Skotheim
Guro E. Lind

Project group:

Cell signalling    
Edward Leithe
   

 

   

The K.G. Jebsen Colorectal Cancer Research Centre.

       

Latest News

 
 

Popular science dissemination of cancer genomics

 

Research from the Department of Molecular Oncology has recently been profiled in three popular science articles.

In an interview in Apollon, Rolf Skotheim discusses why some healthy cells turn into cancer cells.

Bjarne Johannessen and Kaja C. G. Berg have written about colorectal cancer cell lines in the magazine BestPractice. BestPractice is a Norwegian medical journal which focuses on oncology and hematology.

In the same journal, Anita Sveen has written about tumor heterogeneity in metastatic colorectal cancer.

 
 

Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer

 
From left: Anita Sveen, Jarle Bruun and Peter W. Eide.
From left: Anita Sveen, Jarle Bruun and Peter W. Eide.

In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.


More  
 
 

Dr. Jarle Bruun's research profiled in the 2016 National report from the Health Regional Authorities

 
08.08.2017

The report highlights clinically relevant research and projects ongoing in the KG Jebsen Colorectal cancer research centre was selected from the Health Region South East. Specifically, Dr Jarle Bruun's paper identifying the gene Regulator of chromosome condensation 2 (RCC2) as functionally important in colorectal cancer, and furthermore that changes of RCC2 at the DNA and protein level can identify clinically distinct subgroups of patients with inferior survival. This is the first paper that reports clinical relevance of RCC2 in cancer. Bruun has already contributed to two ongoing innovation projects from the Lothe group at the Department of Molecular Oncology, Institute for Cancer Research.

Forskning og innovasjon til pasientens beste - Nasjonal rapport fra spesialisthelsetjenesten 2016


More  
 
 
 


Contact information

Department of Molecular Oncology, Institute for Cancer Research
Oslo University Hospital HE - Norwegian Radium Hospital
Mail address: P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway
Street address: Norwegian Radium Hospital, Montebello
Phone: +47 2278 1728, Switchboard: +47 2293 4000, Fax: +47 2278 1745
E-mail: ragnhild.a.lothe@rr-research.no